Kurt Possinger
Impact in
- Oncology top 1%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Bone health and treatments
- Hematology top 2%
- Multiple Myeloma Research and Treatments
Papers in
- Oncology 58
- Cancer Treatment and Pharmacology 20
- Bone health and treatments 9
- HER2/EGFR in Cancer Research 9
- Hematology 16
- Multiple Myeloma Research and Treatments 13
- Co-authors
- Orhan SezerJan EuckerChristian JakobIvana ZavrskiChuanbing ZangUlrike HeiderDiana LüftnerRudolf Morant
- Journals
- Anti-Cancer Drugs (9 papers)Blood (9 papers)Journal of Clinical Oncology (6 papers)European Journal Of Haematology (5 papers)Journal of Cancer Research and Clinical Oncology (4 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Kurt Possinger
100 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 2.2k
- Hematology 498
- Cancer Research 579
- Biological Psychiatry 94
- Hepatology 272
Countries citing papers authored by Kurt Possinger
This map shows the geographic impact of Kurt Possinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt Possinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt Possinger more than expected).
Fields of papers citing papers by Kurt Possinger
This network shows the impact of papers produced by Kurt Possinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt Possinger. The network helps show where Kurt Possinger may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kurt Possinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 1 | |
| 2 | 2012 | 71 | |
| 3 | 2011 | 10 | |
| 4 | 2008 | 8 | |
| 5 | 2006 | 106 | |
| 6 | 2005 | 66 | |
| 7 | 2005 | 4 | |
| 8 | Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. | 2004 | 19 |
| 9 | Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma. | 2004 | 3 |
| 10 | Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. | 2003 | 26 |
| 11 | 2003 | 12 | |
| 12 | 2003 | 27 | |
| 13 | 2003 | 34 | |
| 14 | 2003 | 41 | |
| 15 | 2002 | 52 | |
| 16 | 2002 | 8 | |
| 17 | 2001 | 63 | |
| 18 | 1999 | 50 | |
| 19 | 1999 | 10 | |
| 20 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Hit paper breakdown → | 1998 | 786 |
About Kurt Possinger
Kurt Possinger is a scholar working on Oncology, Hematology, Genetics, Cancer Research and Biological Psychiatry, having authored 101 papers that have together received 4.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (20 papers), Multiple Myeloma Research and Treatments (13 papers), Breast Cancer Treatment Studies (12 papers), Ubiquitin and proteasome pathways (10 papers), Bone health and treatments (9 papers), Estrogen and related hormone effects (9 papers), HER2/EGFR in Cancer Research (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). The work is most often cited by research in Oncology (2.2k citations), Hematology (498 citations), Cancer Research (579 citations), Biological Psychiatry (94 citations) and Hepatology (272 citations). Kurt Possinger has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Orhan Sezer, Jan Eucker, Christian Jakob, Ivana Zavrski, Chuanbing Zang, Ulrike Heider, Diana Lüftner, Rudolf Morant, Harry Bleiberg and Philippe Rougier. Their work appears in journals such as Anti-Cancer Drugs, Blood, Journal of Clinical Oncology, European Journal Of Haematology and Journal of Cancer Research and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.